Li, X., Lin, X., Wu, Z., Su, Y., Liang, J., Chen, R., . . . Xu, F. (2021). Pristimerin Protects Against OVX-Mediated Bone Loss by Attenuating Osteoclast Formation and Activity via Inhibition of RANKL-Mediated Activation of NF-κB and ERK Signaling Pathways. Drug Des Devel Ther.
Παραπομπή Chicago StyleLi, Xuedong, et al. "Pristimerin Protects Against OVX-Mediated Bone Loss By Attenuating Osteoclast Formation and Activity Via Inhibition of RANKL-Mediated Activation of NF-κB and ERK Signaling Pathways." Drug Des Devel Ther 2021.
Παραπομπή MLALi, Xuedong, et al. "Pristimerin Protects Against OVX-Mediated Bone Loss By Attenuating Osteoclast Formation and Activity Via Inhibition of RANKL-Mediated Activation of NF-κB and ERK Signaling Pathways." Drug Des Devel Ther 2021.